Company Reports

Recent Updates

All Reports

Stock Analyst Note

Sanofi reported third-quarter net sales growth of 14% and business EPS growth of 20% at constant currencies. Management upgraded full-year guidance to low-teens sales growth, up from around 10%, and mid-teens business EPS growth. Ordinary shares closed up 5% from the previous day's close.
Stock Analyst Note

Sanofi reported second-quarter net sales growth of 18% and business EPS growth of 33% at constant currencies, fueled by Dupixent's outstanding performance. Management updated full-year guidance to around 10% sales growth and slightly faster business EPS growth. Sanofi's Paris-listed shares fell 9%.
Stock Analyst Note

Sanofi reported net sales growth of 14% and business EPS growth of 14% at constant currencies. Management affirmed its guidance for high-single-digit sales growth and slightly faster business EPS growth. Shares are about 1% higher than the previous day's close.
Stock Analyst Note

Sanofi reported net sales growth of 7% at constant currency and business earnings per share growth of 13%. Despite lower flu vaccine sales, Dupixent and Altuviiio continued to drive growth, and management reiterated its full-year guidance of low-double-digit business EPS growth.
Stock Analyst Note

Sanofi has entered into an agreement to acquire Blueprint Medicines for $129 per share, or about $9.1 billion. Additional contingent value rights bring the total potential deal value to $9.5 billion. Blueprint is a commercial-stage biotech company focused on mast-cell-driven diseases.
Stock Analyst Note

President Trump released an executive order on May 12 calling for a 30-day negotiation period between the Department of Health and Human Services and the biopharma industry, with the threat of a rule from the Centers for Medicare and Medicaid Services to lower US drug prices if no deal is reached.
Stock Analyst Note

Wide-moat Sanofi’s fourth-quarter results and 2025 guidance were in line with expectations. The company also announced a share buyback program of EUR 5 billion and proposed to increase its dividend to EUR 3.92 per share, a more than 4% increase, which we view as incrementally positive. The outlook for 2025 looks attractive given lack of major loss of exclusivity events, foreign exchange tailwinds, and the potential for significant pipeline news flow. We maintain our fair values of EUR 117 per ordinary share and $63 per US ADR.
Stock Analyst Note

Following President-elect Donald Trump’s Nov. 14 announcement of the nomination of Robert F. Kennedy Jr. as secretary of the US Department of Health and Human Services, there have seen several more nominations for leadership in the 13 HHS divisions, including Dr. Mehmet Oz (Centers for Medicare and Medicaid Services) on Nov. 19, Dr. Marty Makary (US Food and Drug Administration) and Dr. Dave Weldon (Centers for Disease Control and Prevention) on Nov. 22, and Dr. Jay Bhattacharya (National Institutes of Health) on Nov. 26. Overall, we think these selections show a consistent theme of introducing potential disruptive forces to US healthcare, although their lack of experience and the power of career staffers in these agencies could serve to blunt any significant proposed changes. We continue to see obesity drugs and vaccines as areas of potential scrutiny, although without any clarity on proposals, we’re not making any changes to our fair value estimates following these announcements.
Stock Analyst Note

President-elect Donald Trump announced on Nov. 14 that he is nominating Robert F. Kennedy Jr. to be secretary of the Department of Health and Human Services under his new administration in 2025. RFK Jr. has strong views on public health and, if confirmed, could use his position to make changes at several of the 13 HHS divisions. In our Nov. 8 note, we discussed the potential tailwinds of a Trump administration, including possible repeal of the Medicare negotiation provision in the Inflation Reduction Act, less Federal Trade Commission scrutiny of acquisitions, and a likely continuation of lower corporate taxes. However, if RFK’s nomination is confirmed, we expect more “wild card” headwinds to the industry will come to fruition. As the HHS covers the US Food and Drug Administration and the Centers for Disease Control and Prevention, an HHS secretary skeptical of vaccine and obesity drug benefits could work to erode public trust, put up roadblocks for approval of new vaccines, and prevent the CDC from recommending any vaccines that make it through the approval process. With less federal guidance, we think it is possible certain states could waver in support of broad mandates for childhood vaccines. All of these could weigh on sales of vaccines in the US, including covid vaccine makers Moderna and BioNTech and big biopharma vaccine makers like GSK (we model 14% of GSK revenue from US vaccine sales in 2024), Pfizer (12%), Merck (9%), and Sanofi (6%).

Sponsor Center